Is NeuroPace, Inc. (NPCE) a Buy, Sell, or Hold?
NASDAQ : NPCE
NeuroPace, Inc.
$15.75 USD
-$0.33 (-2.05%)
- Volume
- 62.45K
- Average Volume
- 185.6K
- Market Capitalization
- $536.98M
- P/E Ratio
- -24.17
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $19.60
- Year Low
- $7.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.38
Company Overview
NASDAQ
Joel D. Becker
Medical - Devices
Healthcare
NPCE
220
US
USD
Liquidity Metrics
4.87
5.38
4.35
0.91
0.00
Sales & Valuation
$99.99M
5.40
36.74
-54.59
-0.29
Profitability
-$0.66
-$21.46M
-21.67%
-21.67%
-120.74%
-21.81%
P/E Metrics
-24.17
-0.94
-0.94
Analyst Price Target & Rating
$20.00
$20.00
$20.00
1/5
10 Analysts
-21.25%
Financial Health Scores
-2.67
4/9
$70.81M
$98.9M
$84.44M
-$15.41M
Key Metrics (TTM)
$592.66M
5.95
-42.82
5.38
-120.74%
-19.74%
-4.06%
-1.83%
260 days
Company Executives
| Name | Title |
|---|---|
| Scott R. Schaper | Head of Investor Relations |
| Julie Hsu | Vice President & Controller |
| Chris Reese | Senior Vice President of Sales |
| Dylan John | Chief of Operations & Development |
| Katie Keller | Vice President of Marketing |
| Amy Treadwell | Vice President of Human Resources |
| Patrick F. Williams | Chief Financial Officer |
| Martha J. Morrell | Chief Medical Officer |
| Leah Akin | General Counsel & Corporate Secretary |
| Joel D. Becker | Chief Executive Officer, President & Director |
| Rebecca L. Kuhn | Advisor |
Poll Results
No votes yet today — be the first to share your view!
About NeuroPace, Inc. (NASDAQ:NPCE) Stock
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, ... as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
2026-07-15 11:25:15
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
2026-06-15 10:55:33
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
2026-06-11 12:32:09
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
2026-06-10 11:41:25
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
2026-06-02 12:51:12
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
2026-05-29 08:05:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical out.
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
2026-05-29 08:00:00
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si.
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
2026-05-27 12:00:21
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
Frequently Asked Questions
-
What is the current NeuroPace, Inc. (NPCE) stock price?
-
NeuroPace, Inc.(NASDAQ:NPCE) stock price is $15.75 in the last trading session. During the trading session, NPCE stock reached the peak price of $19.6 while $7.563 was the lowest point it dropped to. The percentage change in NPCE stock occurred in the recent session was --2.05% while the dollar amount for the price change in NPCE stock was -$0.33.
-
NPCE's industry and sector of operation?
-
The NASDAQ listed NPCE is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of NPCE?
-
Scott R. Schaper | Head of Investor Relations
Julie Hsu | Vice President & Controller
Chris Reese | Senior Vice President of Sales
Dylan John | Chief of Operations & Development
Katie Keller | Vice President of Marketing -
How many employees does NPCE have?
-
Number of NPCE employees currently stands at 220. NPCE operates from 455 North Bernardo Avenue, Mountain View, CA 94043, US.
-
Link for NPCE official website?
-
Official Website of NPCE is: https://www.neuropace.com
-
How do I contact NPCE?
-
NPCE could be contacted at phone #650 237 2700 and can also be accessed through its website. NPCE operates from 455 North Bernardo Avenue, Mountain View, CA 94043, US.
-
How many shares of NPCE are traded daily?
-
The average number of NPCE shares traded daily for last 3 months was 185.6K.
-
What is the market cap of NPCE currently?
-
The market value of NPCE currently stands at $536.98M with its latest stock price at $15.75